Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Riverside County Sheriff Stan Sniff. His name is suited for detecting drug impairment.
Also made it's way to Yahoo Finance news https://finance.yahoo.com/news/employers-had-convenient-way-test-113000706.html
Pure speculation that the new entity taking over the shell is one of the up and coming CBD companies in Colorado. Will just have to sit back and watch this unfold. I need to see it to believe.
From the Chief Growth Officer of Ecogen Labs on Aug 2nd, 2019:
Any plans on raising capital in the future?
"Yes, 90 MM private with plans to IPO."
Reference: https://www.greenmarketreport.com/executive-spotlight-derek-du-chesne-chief-growth-officer-of-ecogen-laboratories/
How about a reverse merger with Hound Labs using $BLOZF as the shell? Combine the best of both technologies and increase shareholder value.
I'm guessing something may be revealed before the next 10-Q is due, which may mean mid-Nov latest.
Darn. I missed out on discounted shares this morning. $1.61 is a steal deal.
Since it's the Pink sheets, unaudited SEC reports are expected, but if the idea is to be listed in a major stock exchange in the future, then it would be reassuring if the new entity files audited financials right out of the gates. It would also demonstrate the entity's ability to pay an auditing firm.
Is there a certain legal timeframe for the new entity to report or announce the closing of the deal? Isn't it 4 business days after a reverse merger is complete? Is OTC an exception?
"Unless otherwise specified, a report is to be filed or furnished within four business days after occurrence of the event. If the event occurs on a Saturday, Sunday or holiday on which the Commission is not open for business, then the four business day period shall begin to run on, and include, the first business day thereafter."
Form 8-K Item 1.01 https://www.sec.gov/files/form8-k.pdf
Come on $BLOZF, show us something. HL was mentioned again... https://www.inquirer.com/business/weed/thc-breathalyzer-hound-intrinsic-capital-goodwin-doctor-mike-lynn-20191013.html
Nothing new, just on their website now https://nwbio.com/nw-bio-moves-forward-sec-settlement/
Sidetracking, but did someone already post this? https://www.businesswire.com/news/home/20191010005024/en/Advaxis-UCLA-Enter-Collaboration-Glioblastoma-Immunotherapy-Discovery
If you want another data point, I emailed clancy@clancysystems.com with the following questions:
"Are you able to discuss recent changes to your business? I've noticed 6 SEC filings for $CLSI submitted in 4 business days. Why is your company now deciding to be current on the OTC market?"
I received the following response:
Yes, commission-free too. I confirmed yesterday morning. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151564099
Confirmed. No Schwab commission for picking up $CLSI this morning.
Looking at most recent 13G and 13G/A it looks like First Eagle Investment Management, LLC dropped 22,476,546 shares and Bleichroeder Lp picked up 26,476,546 shares. Did they make a deal and Bleichroeder picked up a few extra after?
That's unfortunate. What has come of this world. Sounds like Schwab might be commission-free for OTC. Not sure about Interactive Brokers.
Commission free trading starting tomorrow, load up!
Racing with competition? "Nuclear technology companies Phoenix and SHINE Medical Technologies have achieved a new world record for a nuclear fusion reaction in a steady-state system, the strongest of its kind ever produced on Earth. The reaction yielded 46 trillion (4.6×1013) neutrons per second, eclipsing the previous record by nearly 25% and setting a new standard for neutron generator technology."
https://physicsworld.com/a/record-breaking-fusion-reaction-could-transform-medical-isotope-production/
Starts in 8 min http://wsw.com/webcast/cantor10/drrx/
They have until March 18th, 2020 to meet the $1.00 Minimum Bid Price Requirement and can be eligible to extend that date by 180 more days.
"In accordance with Nasdaq listing rules, the Company has been provided an initial period of 180 calendar days, or until March 18, 2020 (the “Compliance Date”), to regain compliance with the Minimum Bid Price Requirement. If, at any time during this 180-day period, the closing bid price of the Company’s common stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide the Company written confirmation of compliance with the Minimum Bid Price Requirement and the matter will be closed. If the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period."
https://fintel.io/doc/sec-ghsi-8k-guardion-health-sciences-2019-september-26-18165
Found a rough answer in the latest news release, "Going forward, the Company plans to expand their product line by developing medical isotope generators within the next two years."
https://www.newsfilecorp.com/release/48423
NCT0383774 update posted Oct 1st https://clinicaltrials.gov/ct2/history/NCT03837743?A=3&B=4&C=merged#StudyPageTop
$DRRX at a discount today?
Currently doing some DD ON $CLSI. So they also make the Denver Boot? https://www.cpr.org/2019/09/09/yes-the-denver-boot-comes-from-denver-now-colorado-is-deciding-how-private-business-can-use-it/
$ACRX amended its supply agreement with SpecGX LLC to extend the term through December 31, 2022 https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13662267
NCT03917407 Study start date changed to Nov 1st https://clinicaltrials.gov/ct2/history/NCT03917407?A=4&B=5&C=merged#StudyPageTop
We have a competitor in Phase 3 https://www.cidara.com/rezafungin/
Clinical Trial Study: https://clinicaltrials.gov/ct2/show/NCT03667690
$ATNM had their independent DMC review trial data at 25% enrollment for their Phase 3 Sierra study. They recently achieved 50% enrollment, so hoping there are some meetings again.
Past update: https://www.globenewswire.com/news-release/2018/06/26/1529536/0/en/Actinium-Pharmaceuticals-Announces-Dosing-of-38th-Patient-and-25-Percent-Enrollment-in-Iomab-B-Pivotal-SIERRA-Trial.html
DMC: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/establishment-and-operation-clinical-trial-data-monitoring-committees
Reminder: $SCYX at Ladenburg Thalmann Healthcare Conference tomorrow http://wsw.com/webcast/ladenburg5/scyx/index.aspx
Nothing new, but NCT03432260 update formally posted today https://clinicaltrials.gov/ct2/history/NCT03432260?A=5&B=6&C=merged#StudyPageTop
DMC soon?
NCT03734991 Study updated today and completed early https://clinicaltrials.gov/ct2/show/NCT03734991
What $AMZN? No hydrogen powered vehicles? https://www.cnbc.com/amp/2019/09/19/amazon-is-purchasing-100000-rivian-electric-vans.html
8-K from Nov 21st, 2018 shows what the CSV-2000 might look like. Check out page 19 of the PDF https://guardionhealth.com/wp-content/uploads/2018/11/tv507724_Guardion-Health-Sciences-Inc.-_8-K_As-Filed-bannerless.pdf
Nevermind. That's for antibiotics rather than antifungal.